Claims for Patent: 8,084,419

Summary for Patent: 8,084,419

Title:	Pharmaceutical compositions for sustained drug delivery
Abstract:	Sustained delivery formulations comprising a water-insoluble complex of a peptide and a plurality of ligands are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. Methods of making the complexes of the invention, and methods of these complexes are also disclosed.
Inventor(s):	Gefter; Malcolm L. (Lincoln, MA)
Assignee:	GlaxoSmithKline, LLC (Philadelphia, PA)
Application Number:	11/173,901
Patent Claims:	1. A composition comprising: (a) a plurality of peptide molecules; (b) a plurality of ligand molecules for said peptide molecules, wherein one or more ligand molecules bind to each of said plurality of peptide molecules, each of said ligand molecules being positively charged; and (c) a negatively charged carrier macromolecule; wherein said plurality of peptide molecules, said plurality of ligand molecules and said carrier macromolecule together form a water insoluble complex. 2. The composition of claim 1, wherein each of said plurality of ligand molecules is a peptidic compound. 3. The composition of claim 1, wherein each of said plurality of ligand molecules is a non-peptidic compound. 4. The composition of claim 1, wherein each of said plurality of peptide molecules is selected from the group consisting of insulin, erythropoietin, growth hormone, bradykinin, parathyroid hormone, adenocorticotrophic hormone, calcitonin, vasopressin, angiotensin, desmopressin, luteinizing hormone-releasing hormone, somatostatin, glucagon, somatomedin, oxytocin, gastrin, secretin, melanocyte stimulating hormone, beta-endorphin, enkephalin, neurotensin, thyroid releasing hormone, macrophage stimulating factor, CCR-5, tumor necrosis factor (TNF), growth hormone releasing factor (GRF), RGD, and interleukin. 5. The composition of claim 1, wherein the each of said plurality of peptide molecules is an LHRH analogue. 6. The composition of claim 1, wherein the composition provides sustained delivery of the peptide to a subject for at least one week after the composition is administered to the subject. 7. The composition of claim 1, wherein the composition provides sustained delivery of the peptide to a subject for at least two weeks after the composition is administered to the subject. 8. The composition of claim 1, wherein the composition provides sustained delivery of the peptide to a subject for at least four weeks after the composition is administered to the subject. 9. The composition of claim 1, wherein each of said plurality of peptide molecules is releasable in vivo in a pharmaceutically active form. 10. The composition of claim 1, wherein the carrier macromolecule is selected from the group consisting of poly(allylamine), poly(vinylamine), poly(ethyleneimine), N-alkylated poly(allylamine), N-alkylated poly(vinylamine) and N-alkylated poly(ethyleneimine). 11. The composition of claim 1, wherein the carrier macromolecule is carboxymethylcellulose. 12. The composition of claim 1, wherein each of said ligand molecules is a poly(arginine) molecule. 13. The composition of claim 1, wherein each of said ligand molecules is a poly(d-arginine) molecule. 14. The composition of claim 1, wherein each of said ligand molecules is a poly(lysine) molecule. 15. The composition of claim 1, wherein said ligand comprises a binding sequence and a charged sequence. 16. The composition of claim 15, wherein said binding sequence and said charged sequence overlap. 17. The composition of claim 15, wherein said charged sequence is a sequence that facilitates transport across a cell membrane. 18. A composition comprising: (a) a plurality of peptide molecules; (b) a plurality of ligand molecules for said peptide molecules, wherein one or more ligand molecules bind to each of said plurality of peptide molecules, each of said ligand molecules comprising a binding sequence and a positively charged sequence; and (c) a negatively charged carrier macromolecule; wherein said plurality of peptide molecules, said plurality of ligand molecules and said carrier macromolecule together form a water insoluble complex. 19. The composition of claim 18, wherein said binding sequence and said charged sequence overlap. 20. A composition comprising: (a) a plurality of peptide molecules; (b) a plurality of ligand molecules for said peptide molecules, wherein one or more ligand molecules bind to each of said plurality of peptide molecules, each of said ligand molecules being positively charged; and (c) carboxymethylcellulose; wherein said plurality of peptide molecules, said plurality of ligand molecules and said carboxymethylcellulose together form a water insoluble complex. 21. A composition comprising: (a) a plurality of peptide molecules, wherein each of said plurality of peptide molecules is selected from the group consisting of insulin, erythropoietin, growth hormone, bradykinin, parathyroid hormone, adenocorticotrophic hormone, calcitonin, vasopressin, angiotensin, desmopressin, luteinizing hormone-releasing hormone, somatostatin, glucagon, somatomedin, oxytocin, gastrin, secretin, melanocyte stimulating hormone, beta-endorphin, enkephalin, neurotensin, thyroid releasing hormone, macrophage stimulating factor, CCR-5, tumor necrosis factor (TNF), growth hormone releasing factor (GRF), RGD, an LHRH analogue, and interleukin; (b) a plurality of ligand molecules for said peptide molecules, wherein one or more ligand molecules bind to each of said plurality of peptide molecules, each of said ligand molecules being positively charged; and (c) a negatively charged carrier macromolecule; wherein said plurality of peptide molecules, said plurality of ligand molecules and said carrier macromolecule together form a water insoluble complex. 22. A composition comprising: (a) a plurality of peptide molecules, wherein each of said plurality of peptide molecules is selected from the group consisting of insulin, erythropoietin, growth hormone, bradykinin, parathyroid hormone, adenocorticotrophic hormone, calcitonin, vasopressin, angiotensin, desmopressin, luteinizing hormone-releasing hormone, somatostatin, glucagon, somatomedin, oxytocin, gastrin, secretin, melanocyte stimulating hormone, beta-endorphin, enkephalin, neurotensin, thyroid releasing hormone, macrophage stimulating factor, CCR-5, tumor necrosis factor (TNF), growth hormone releasing factor (GRF), RGD, an LHRH analogue, and interleukin; (b) a plurality of ligand molecules for said peptide molecules, wherein one or more ligand molecules bind to each of said plurality of peptide molecules, each of said ligand molecules being positively charged; and (c) carboxymethylcellulose; wherein said plurality of peptide molecules, said plurality of ligand molecules and said carboxymethylcellulose together form a water insoluble complex.

Details for Patent 8,084,419

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2020-09-13